CA2340475A1 - Orphan receptor - Google Patents
Orphan receptor Download PDFInfo
- Publication number
- CA2340475A1 CA2340475A1 CA002340475A CA2340475A CA2340475A1 CA 2340475 A1 CA2340475 A1 CA 2340475A1 CA 002340475 A CA002340475 A CA 002340475A CA 2340475 A CA2340475 A CA 2340475A CA 2340475 A1 CA2340475 A1 CA 2340475A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid sequence
- receptor
- relates
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention relates to a novel estrogen receptor-related nuclear receptor, hereinafter termed "ER.beta." having the amino acid sequence of Figs. 1,13A or 14A or substantially the same amino acid sequence as the amino acid sequence shown in Figs. 1, 13A or 13B or an amino acid sequence functionally similar to that sequence. The invention also relates to DNA
sequences encoding the receptor. The receptor may be useful in isolating molecules for the treatment of disorders such as prostate cancer, benign prostatic hyperplasia, osteoporosis or cardiovascular disorders and in the testing of substances for estrogenic and other hormonal effects.
sequences encoding the receptor. The receptor may be useful in isolating molecules for the treatment of disorders such as prostate cancer, benign prostatic hyperplasia, osteoporosis or cardiovascular disorders and in the testing of substances for estrogenic and other hormonal effects.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9518272.1 | 1995-09-08 | ||
GBGB9518272.1A GB9518272D0 (en) | 1995-09-08 | 1995-09-08 | Orphan receptor |
GBGB9605550.4A GB9605550D0 (en) | 1996-03-15 | 1996-03-15 | Orphan receptor |
GB9605550.4 | 1996-03-15 | ||
GB9607532.0 | 1996-04-11 | ||
GBGB9607532.0A GB9607532D0 (en) | 1996-04-11 | 1996-04-11 | Orphan receptor |
GBGB9609576.5A GB9609576D0 (en) | 1996-05-08 | 1996-05-08 | Orphan receptor |
GB9609576.5 | 1996-05-08 | ||
CA002201098A CA2201098C (en) | 1995-09-08 | 1996-09-09 | Orphan receptor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002201098A Division CA2201098C (en) | 1995-09-08 | 1996-09-09 | Orphan receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2340475A1 true CA2340475A1 (en) | 1997-03-13 |
CA2340475C CA2340475C (en) | 2002-08-20 |
Family
ID=27508619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002340475A Expired - Fee Related CA2340475C (en) | 1995-09-08 | 1996-09-09 | Orphan receptor |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2340475C (en) |
-
1996
- 1996-09-09 CA CA002340475A patent/CA2340475C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2340475C (en) | 2002-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2201098A1 (en) | Orphan receptor | |
AU1378499A (en) | Methods for treating prostate tumors using radioactive compositions | |
MXPA00012586A (en) | Glycosulfopeptides and methods of synthesis and use thereof. | |
EP1310509A3 (en) | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | |
WO1997044063A3 (en) | Dha-pharmaceutical agent conjugates | |
BR9710636A (en) | Analog of cyclized somatostatin of the backbone, use of it, pharmaceutical composition, and, process of treatment of endocrine disorders, neoplasms or metabolic disorders. | |
EP0831933A4 (en) | Site specific binding system, imaging compositions and methods | |
AU2287495A (en) | Methods and compositions for treating depression and other disorders using optically pure s(+) fluoxetine | |
BG103436A (en) | Conjugates applicable in the treatment of the prostate gland cancer | |
AU1316000A (en) | Compositions and methods for treating benign prostatic hyperplasia using tocotrienols | |
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
EP1009755A4 (en) | Steroid sulfatase inhibitors and methods for making and using the same | |
EP0880410A4 (en) | Passivation composition and process for coating | |
AU4100199A (en) | Compositions and methods for enhancing protein anabolism and detoxification | |
IL128872A0 (en) | TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods | |
WO1997029199A3 (en) | Prostate specific antigen peptides and uses thereof | |
AU6633694A (en) | Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides | |
CA2340475A1 (en) | Orphan receptor | |
IL132094A0 (en) | Methods and compositions for treatment of ovarian cancer | |
Miller et al. | Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His | |
EP1512755A3 (en) | Markers for prostate cancer | |
AU1719500A (en) | Method for augmenting the inotropic effects of beta-adrenergic agonists using pyruvate therapy | |
EP1077892A4 (en) | Process and composition for improving the uniformity of size application | |
AU2390700A (en) | Polypeptidic compositions and methods for the treatment of tumors | |
WO1999029719A3 (en) | Pancreatic-derived factors, and uses related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140909 |